Want to see BIO.B full AI Analyst Report?
Bio-Rad Laboratories, Inc. Class B (BIO.B) Financial Statements
Bio-Rad Laboratories, Inc. Class B Financial Overview
Bio-Rad Laboratories, Inc. Class B's market cap is currently $10.00B. The company's EPS TTM is $8.33; its P/E ratio is 44.68; Bio-Rad Laboratories, Inc. Class B is estimated to report earnings on November 4, 2026, and the estimated EPS forecast is $2.23. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.58B | $ 2.57B | $ 2.67B | $ 2.80B | $ 2.92B |
| Gross Profit | $ 1.34B | $ 1.38B | $ 1.43B | $ 1.57B | $ 1.64B |
| Operating Income | $ 270.50M | $ 269.00M | $ 337.80M | $ 482.62M | $ 500.34M |
| EBITDA | $ 1.21B | $ -2.14B | $ -654.80M | $ -4.53B | $ 5.59B |
| Net Income | $ 759.90M | $ -1.84B | $ -637.32M | $ -3.63B | $ 4.25B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.54B | $ 1.66B | $ 1.61B | $ 1.79B | $ 869.92M |
| Total Assets | $ 10.58B | $ 9.36B | $ 12.30B | $ 13.50B | $ 17.80B |
| Total Debt | $ 1.53B | $ 1.37B | $ 1.41B | $ 1.39B | $ 223.38M |
| Net Debt | $ 999.20M | $ 886.60M | $ 1.00B | $ 953.88M | $ -247.41M |
| Total Liabilities | $ 3.12B | $ 2.79B | $ 3.56B | $ 3.89B | $ 4.11B |
| Stockholders' Equity | $ 7.45B | $ 6.57B | $ 8.74B | $ 9.62B | $ 13.69B |
| Cash Flow | |||||
| Free Cash Flow | $ 374.60M | $ 266.20M | $ 218.26M | $ 80.29M | $ 535.72M |
| Operating Cash Flow | $ 532.20M | $ 455.20M | $ 374.94M | $ 194.45M | $ 669.46M |
| Investing Cash Flow | $ -189.70M | $ -160.20M | $ 20.21M | $ -1.21B | $ -797.38M |
| Financing Cash Flow | $ -283.20M | $ -218.80M | $ -425.65M | $ 973.58M | $ -55.43M |
Currency in USD